That is, of course always a possibility but why would you want to insist on it without considering the merits of the product itself? Have you tried it?
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025